Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchStudy completedNCT02144623
What this trial is testing

Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Lund University Hospital 4
Testing effectiveness (Phase 2)Study completedNCT00989586
What this trial is testing

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
Beth Christian 35
Very early researchUnknownNCT03407859
What this trial is testing

Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

Who this might be right for
Therapy Related Leukemia
Zhujiang Hospital 100
Not applicableStudy completedNCT04884477
What this trial is testing

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Who this might be right for
COVID-19Immunosuppressed HostConvalescent Plasma+1 more
Mayo Clinic 342
Early research (Phase 1)Looking for participantsNCT07491900
What this trial is testing

HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus Erthematosus (SLE)Lupus Nephritis (LN)Extra-renal Lupus (ERL)
Hinge Bio 30
Testing effectiveness (Phase 2)UnknownNCT03207178
What this trial is testing

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Who this might be right for
Recurrent or Refractory B Cell Malignancy
Shanghai Longyao Biotechnology Inc., Ltd. 20
Large-scale testing (Phase 3)UnknownNCT02186574
What this trial is testing

Tenofovir to Prevent HBV Reactivation

Who this might be right for
Hepatitis BLymphomaNon-Hodgkin
University Health Network, Toronto 184
Large-scale testing (Phase 3)Ended earlyNCT01039376
What this trial is testing

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Who this might be right for
Leukaemia, Lymphocytic, Chronic
Novartis Pharmaceuticals 480
Testing effectiveness (Phase 2)Study completedNCT03196830
What this trial is testing

CAR-T for R/R B-NHL

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin LymphomaCAR - T CD19/CD20/CD22/CD30
The First Affiliated Hospital of Soochow University 168
Testing effectiveness (Phase 2)Study completedNCT04083014
What this trial is testing

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Who this might be right for
Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Study completedNCT00517049
What this trial is testing

PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Who this might be right for
Non-Hodgkin's Lymphoma
Genentech, Inc. 49
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Early research (Phase 1)Not Yet RecruitingNCT07701889
What this trial is testing

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Hematologic Diseases
Roswell Park Cancer Institute 21
Testing effectiveness (Phase 2)UnknownNCT02315118
What this trial is testing

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Who this might be right for
B-Cell Chronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
National University Hospital, Singapore 18
Testing effectiveness (Phase 2)Study completedNCT00521560
What this trial is testing

Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

Who this might be right for
Primary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's Lymphoma
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH 28
Early research (Phase 1)Study completedNCT02651662
What this trial is testing

Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Lymphoma
Regeneron Pharmaceuticals 105
Early research (Phase 1)Ended earlyNCT00036855
What this trial is testing

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Who this might be right for
AIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaPost-transplant Lymphoproliferative Disorder+4 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT00366418
What this trial is testing

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Who this might be right for
Refractory Chronic Lymphocytic Leukemia
National Heart, Lung, and Blood Institute (NHLBI) 4
Testing effectiveness (Phase 2)WithdrawnNCT00092274
What this trial is testing

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Who this might be right for
Lymphoma, Follicular
GlaxoSmithKline
Early research (Phase 1)Looking for participantsNCT07775508
What this trial is testing

In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Chinese PLA General Hospital 18
Next Page